echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Immunomodulation vaccine sealed FDA breakthrough therapy in combination with anti-PD-1 antibodies to treat melanoma

    Immunomodulation vaccine sealed FDA breakthrough therapy in combination with anti-PD-1 antibodies to treat melanoma

    • Last Update: 2021-01-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Cancer immunotherapy has become one of the mainstream treatments for many types of cancer.
    anti-PD-1 antibody is intended to release the potential of human T-cells to kill tumors by eliminating immunosuppression mediated by PD-1 signaling pathologies.
    , there are other ingredients that inhibit T-cell activity in the tumor micro-environment, including a variety of immunosuppressive cells.
    IO102 and IO103 are "first-in-class" immunomodulation vaccines developed by IO Biotech, based on IO Biotech's proprietary T-win technology platform.
    the platform is to stimulate T-cell responses that target and directly kill immunosuppressive and tumor cells by injecting a vaccine.
    IO102 is designed to activate specific T cells that target IDO proteins, while IO103 activates specific T cells that target PD-L1.
    specific T cells that are activated can kill immunosuppressive and tumor cells that express IDO and PD-L1. The immunomodulation vaccine developed by the
    T-win technology platform directly kills specific T-cell responses to targeted immunosuppressive and tumor cells (Photo: IO Biotech.com) This breakthrough therapy was awarded based on data from Phase 1/2 clinical trials, with 30 metastases receiving IO102, IO103 and anti-PD-1 antibody therapy.
    the IO102 and IO103 vaccines combined with nivolumab have encouraging early efficacy data, according to data recently published in the latest summary of the Virtual Congress of the European EsMO.
    combined therapy achieved a total remission rate (ORR) of 79% and 45% of patients received complete remission (CR).
    resources: the Food and Drug Administration (FDA) grants IO Biotech background therapy designation for IO102 and IO103 in integration with anti-PD-1 in unresectable/metast melanoma. Retrieved December 16, 2020, from
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.